30 octobre 2018

ORPHELIA at the 2018 SIOP meeting in Kyoto (Japan)
30 octobre 2018

The 50th Annual Congress of the International Society of Paediatric Oncology will take place November 16-19, 2018 in Kyoto, Japan. SIOP is the only global multidisciplinary society entirely devoted to paediatric and adolescent cancer. The society has over 1500 members worldwide including doctors, nurses, other health-care professionals, scientists and researchers. Our members are dedicated to increasing knowledge about all aspects of childhood cancer. https://siop.kenes.com/2018#.W9iK1_ZFxoI Please meet us there (contact: jeremy.bastid@orphelia-pharma.eu and hugues.bienayme@orphelia-pharma.eu).
[ Read more ]
30 octobre 2018

ORPHELIA at Bioeurope in Copenhagen, Denmark
30 octobre 2018

ORPHELIA Pharma will be present in Copenhagen on November 2018, 5th to 7th, for the annual BIO-Europe Congress. This event is the Europe’s largest partnering conference serving the global biotechnology industry. Do not hesitate to contact us in order to meet at this occasion (contact : gilles.alberici@orphelia-pharma.eu). More info at: https://ebdgroup.knect365.com/bioeurope/  
[ Read more ]
22 octobre 2018

ORPHELIA Pharma has been awarded a €1m loan from Bpifrance
22 octobre 2018

Paris and Lyon, October 22, 2018 – ORPHELIA Pharma, a French biopharmaceutical company dedicated to the development and marketing of pediatric drugs in the fields of oncology and neurology, announces today that it has obtained the support of Bpifrance through a ERDF (European Regional Development Fund) innovation loan of one million Euros co-financed by the European Union and the Auvergne Rhône-Alpes region. This grant aims to support the development and industrialization of the first pediatric formulation of an essential drug as a salvage therapy of a rare pediatric cancer. « We are delighted to receive the support from Bpifrance which allows us to accelerate the development of our product in this pediatric indication whose unmet medical need is huge« , comments Jérémy Bastid, Chief Development Officer of ORPHELIA Pharma. « This product has a formulation specially adapted for young children and has been developed in close collaboration with clinicians since 2017. This grant will contribute to the development cost of the product until it becomes available to patients in 2 to 3 years« , adds Hugues Bienaymé, General Manager. About ORPHELIA Pharma Based in Paris and Lyon, ORPHELIA Pharma SAS is a French biopharmaceutical company dedicated to the development and marketing of oncology and neurology pediatric drugs. Its mission is to significantly improve essential medicines administered to children through the development of efficient, reliable and safe drugs with child-friendly formulations. ORPHELIA Pharma also leads innovative R&D projects through academic and industrial partnerships. Key investors include initiative OCTALFA (lead investor) and Pierre Fabre Medicament.
[ Read more ]
1 octobre 2018

Granting of the marketing authorization for Kigabeq®
1 octobre 2018

Paris and Lyon, October 1st, 2018 – ORPHELIA Pharma, a French biopharmaceutical company dedicated to the development and marketing of pediatric drugs in the fields of oncology and neurology, announces today that the European Commission has granted Kigabeq® a European marketing authorization. Kigabeq® is the first pediatric formulation of vigabatrin, an essential antiepileptic drug and will be available as scored soluble tablets of 100 mg and 500 mg strengths. Kigabeq® is expected to be used as first-line treatment for infantile spasms, an extremely severe early childhood encephalopathic epilepsy. Kigabeq® has been developed exclusively for children and will be granted a PUMA (Paediatric Use Marketing Authorization). « This approval is a key milestone for ORPHELIA Pharma as Kigabeq® represents the first in a series of pediatric-focused products we plan to launch. We believe it addresses important pediatric needs and will meaningfully improve the lives of children » comments Hugues Bienaymé, Founder and General Manager. « We can now focus on launching Kigabeq® in France and building relationships with distribution partners to commercialize Kigabeq® throughout Europe ». « This Marketing Authorization comes at the right time for ORPHELIA Pharma and the company will now structure itself upon this first medicine in which we have great expectations » says Gilles Alberici, President. « Our vision is to develop and bring new pediatric drugs with age-adapted formulations to the market for the treatment of life-threatening orphan indications. Today’s milestone is a first step on this exciting journey ». About infantile spasms Infantile spasms, or West Syndrome, is an early childhood epileptic encephalopathy which combines axial spasms in cluster, a marked psychomotor delay and an hypsarythmic electroencephalogram. It is a rare disease with an estimated incidence of around 5 per 10,000 living births. It affects infants who were previously normal or children with impaired cognitive development. Children with infantile spasms must be treated rapidly for spasms cessation and to improve prognosis. About ORPHELIA Pharma Based in Paris and Lyon, ORPHELIA Pharma SAS is a French biopharmaceutical company dedicated to the development and marketing of oncology and neurology pediatric drugs. Its mission is to significantly improve essential medicines administered to children through the development of efficient, reliable and safe drugs with child-friendly formulations. ORPHELIA Pharma also leads innovative R&D projects through academic and industrial partnerships. Key investors include initiative OCTALFA (lead investor) and Pierre Fabre Medicament.
[ Read more ]